Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in Schizophrenia
NCT00455715Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ASP-001 in schizophrenia (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Cognitive Functioning (Verbal Memory, Fluency, Attention, Spatial Memory, Motor Speed, Executive Function) at 12 days. Started Feb 2006; status: completed.
02
Drugs
ASP-001
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00455715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00455715.